UA84749C2 - Антагонисты рецептора pgd2 для лечения воспалительных заболеваний - Google Patents

Антагонисты рецептора pgd2 для лечения воспалительных заболеваний

Info

Publication number
UA84749C2
UA84749C2 UAA200611678A UAA200611678A UA84749C2 UA 84749 C2 UA84749 C2 UA 84749C2 UA A200611678 A UAA200611678 A UA A200611678A UA A200611678 A UAA200611678 A UA A200611678A UA 84749 C2 UA84749 C2 UA 84749C2
Authority
UA
Ukraine
Prior art keywords
heading
treatment
normal
receptor antagonists
inflammatory diseases
Prior art date
Application number
UAA200611678A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Эми М. Элдер
Кевин Т. Спротт
Син Дж. Харрисон
Фредерик А. Хикс
Кристелль С. Рену
Доминик Рейнольдс
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of UA84749C2 publication Critical patent/UA84749C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • C07D215/44Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UAA200611678A 2004-04-07 2005-04-07 Антагонисты рецептора pgd2 для лечения воспалительных заболеваний UA84749C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56041004P 2004-04-07 2004-04-07

Publications (1)

Publication Number Publication Date
UA84749C2 true UA84749C2 (ru) 2008-11-25

Family

ID=34965223

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200611678A UA84749C2 (ru) 2004-04-07 2005-04-07 Антагонисты рецептора pgd2 для лечения воспалительных заболеваний

Country Status (21)

Country Link
EP (1) EP1740547A1 (no)
JP (1) JP2007532555A (no)
KR (1) KR20070002085A (no)
CN (1) CN101018770A (no)
AR (1) AR048528A1 (no)
AU (1) AU2005233125A1 (no)
BR (1) BRPI0509668A (no)
CA (1) CA2561564A1 (no)
CL (1) CL2008000069A1 (no)
CR (1) CR8659A (no)
EC (1) ECSP066977A (no)
IL (1) IL178328A0 (no)
MA (1) MA28566B1 (no)
MX (1) MXPA06011540A (no)
NO (1) NO20065107L (no)
RU (1) RU2006138603A (no)
TN (1) TNSN06320A1 (no)
TW (1) TW200538127A (no)
UA (1) UA84749C2 (no)
WO (1) WO2005100321A1 (no)
ZA (1) ZA200608955B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006216713A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
WO2007014851A2 (en) 2005-07-29 2007-02-08 F. Hoffmann-La Roche Ag Indol-3-yl-carbonyl-piperidin and piperazin derivatives
ES2618352T3 (es) 2006-06-16 2017-06-21 The Trustees Of The University Of Pennsylvania Antagonistas del receptor de prostaglandina D2 para el tratamiento de la alopecia androgenética
CA2661017A1 (en) 2006-08-24 2008-02-28 Novartis Ag Organic compounds
JPWO2008029924A1 (ja) 2006-09-08 2010-01-21 大日本住友製薬株式会社 環状アミノアルキルカルボキサミド誘導体
US8236835B2 (en) 2006-09-22 2012-08-07 Novartis Ag Heterocyclic inhibitors of stearoyl-CoA desaturase
KR20090091337A (ko) 2006-12-20 2009-08-27 노파르티스 아게 Scd 억제제로서의 2-치환 5-원 헤테로사이클
EP2199283A1 (en) 2007-09-27 2010-06-23 Kowa Company, Ltd. Prophylactic and/or therapeutic agent for anemia, comprising tetrahydroquinoline compound as active ingredient
DE602008005796D1 (de) 2007-12-14 2011-05-05 Pulmagen Therapeutics Asthma Ltd Indole und ihre therapeutische verwendung
JP2011102241A (ja) * 2008-03-04 2011-05-26 Dainippon Sumitomo Pharma Co Ltd 新規1−アミノカルボニルピペリジン誘導体
WO2010022320A2 (en) 2008-08-22 2010-02-25 Baxter International Inc. Polymeric benzyl carbonate-derivatives
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
EP2415764A4 (en) 2009-03-31 2012-08-08 Kowa Co PROPHYLACTIC AND / OR THERAPEUTIC AGENT AGAINST ANEMIA WITH A TETRAHYDROCHINOLINE COMPOUND AS AN ACTIVE SUBSTANCE
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2496945B1 (en) 2009-11-05 2015-04-01 GlaxoSmithKline LLC Novel process
RU2013104506A (ru) 2010-07-05 2014-08-10 Актелион Фармасьютиклз Лтд 1-фенилзамещенные производные гетероциклила и их применение в качестве модуляторов рецептора простагландина d2
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2720545B1 (en) 2011-06-17 2016-11-30 Merck Sharp & Dohme Corp. Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
AU2012351342A1 (en) 2011-12-16 2014-07-24 Atopix Therapeutics Limited Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
RU2014129613A (ru) 2011-12-21 2016-02-10 Актелион Фармасьютиклз Лтд Гетероциклильные производные и их применение в качестве модуляторов рецептора простагландина d2
US9169270B2 (en) 2012-07-05 2015-10-27 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
EP3256121B1 (en) 2015-02-13 2024-08-07 INSERM - Institut National de la Santé et de la Recherche Médicale Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
KR20180031019A (ko) 2015-07-30 2018-03-27 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Pgd2에 의한 모발 성장 억제에 대한 민감성의 검출을 위한 인간 dp―2 유전자의 단일 뉴클레오티드 다형성 대립유전자
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
SG11202009438UA (en) 2018-04-18 2020-11-27 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN113201316B (zh) * 2021-04-25 2022-08-26 西南石油大学 温度/CO2/pH多重响应性乳化剂和乳状液及其应用
CN116425623B (zh) * 2023-04-10 2024-02-13 大连凯飞化学股份有限公司 一锅法合成3,5-二氯-4-甲基苯甲酸的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2186065C1 (ru) * 1998-03-31 2002-07-27 Сионоги Энд Ко., Лтд. Способ получения производных 5-гидрокси-бензо[b]тиофен-3-карбоновой кислоты (варианты) и производные бензо[b]тиофеновой кислоты
KR100591998B1 (ko) * 2001-04-30 2006-06-22 화이자 프로덕츠 인크. 4-아미노퀴놀린 유도체용 중간체로서 유용한 화합물
JP2003321471A (ja) * 2002-04-30 2003-11-11 Fuji Photo Film Co Ltd ラクタム化合物及びその製造方法
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7211672B2 (en) * 2002-10-04 2007-05-01 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05003660A (es) * 2002-10-21 2005-06-08 Warner Lambert Co Derivados de quinolina como antagonistas de crth2.
WO2004052863A1 (ja) * 2002-12-06 2004-06-24 Kyowa Hakko Kogyo Co., Ltd. 抗炎症剤
EP1435356A1 (en) * 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists

Also Published As

Publication number Publication date
MA28566B1 (fr) 2007-05-02
AU2005233125A1 (en) 2005-10-27
ECSP066977A (es) 2006-12-29
TW200538127A (en) 2005-12-01
CA2561564A1 (en) 2005-10-27
IL178328A0 (en) 2007-02-11
BRPI0509668A (pt) 2007-10-09
CN101018770A (zh) 2007-08-15
CL2008000069A1 (es) 2008-05-16
MXPA06011540A (es) 2007-01-26
RU2006138603A (ru) 2008-05-20
AR048528A1 (es) 2006-05-03
CR8659A (es) 2007-06-08
EP1740547A1 (en) 2007-01-10
NO20065107L (no) 2006-12-01
ZA200608955B (en) 2009-05-27
WO2005100321A1 (en) 2005-10-27
JP2007532555A (ja) 2007-11-15
KR20070002085A (ko) 2007-01-04
TNSN06320A1 (en) 2008-02-22

Similar Documents

Publication Publication Date Title
UA84749C2 (ru) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
WO2004032848A3 (en) Pgd2 receptor antagonists for the treatment of inflammatory diseases
MX2007003335A (es) Acidos aceticos de bencimidazol que muestran antagonismo de receptor crth2 y usos de los mismos.
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
NO20074961L (no) Imidazopyridazinforbindelser
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
ATE250577T1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
WO2004098589A8 (en) 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
EA200401309A1 (ru) Тризамещённые гетероарилы и способы их получения и применения
MX2007007220A (es) Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos.
TW200640869A (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
EA200500173A1 (ru) Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
MY141200A (en) Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
ATE323686T1 (de) Substituierte 2-arylbenzazole und ihre verwendung als antitumorale mittel
BRPI0409393A8 (pt) composto, composição farmacêutica, e, métodos para modulação de atividade de receptor de quimiocina em um mamífero, para tratamento, melhora, controle ou redução do risco de um distúrbio ou doença inflamatório e imunorregulatório, e de artrite reumatóide
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
MX2007002833A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios.
WO2006114666A8 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
EA200602081A1 (ru) Пиридиновые производные алкилоксиндолов в качестве агентов, активных в отношении рецептора 5-нт7
BR9607443A (pt) Composto de 4-aminotetraidrobenzisoxazol ou-isatiazol composição farmacêutica e utilização do composto